InsidersTradesSigma
Milestone Scientific INC. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Milestone Scientific INC. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Milestone Scientific INC. has recorded 105 reports. Market capitalisation: €28.8m. The latest transaction was filed on 16 September 2025 (Cession). Among the most active insiders: OSSER LEONARD. All data is free.
105
Insider Decl.
0
Thresholds
€154,430
7 ops.
Buy Volume
€656,793
47 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Milestone Scientific INC. Strong Buy (bullish), based on 2 analysts. Average price target: US$1.00.
37Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,698 of 25,921 companies
20.5
score / 100
Value11
Quality30
FCF yld·
Earn yld-17%
EV/EBITDA·
ROE-135%
Gross mgn71%
Net mgn-64%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 16 September 2025
Declarations105 total
10,000 shares@ US$0.5946.4% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-029170:0
10,000 shares@ US$0.646.9% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-023233:0
26,855 shares@ US$0.910426.9% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019933:0
60,200 shares@ US$0.901459.7% of flowCommon Stock, Par Value $0.001SEC:0001437749-25-019933:1
20,000 shares@ US$0.77666.2% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-038113:0
107,984 shares@ US$0.935.0% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-031909:0
209 shares@ US$1.000.1% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-030125:0
1,000 shares@ US$1.000.4% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-029896:0
112,356 shares@ US$0.894.8% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028154:0
123,560 shares@ US$0.8940.7% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028157:0
134,832 shares@ US$0.8917.2% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028155:0
112,356 shares@ US$0.8915.1% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028153:0
134,834 shares@ US$0.8930.8% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-028158:0
141,913 shares@ US$0.956.5% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-027506:0
22,127 shares@ US$0.551.8% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-012873:0
56,065 shares@ US$0.544.5% of flowCommon Stock, Par Value $0.001SEC:0001437749-24-012753:0
125,000 shares@ US$0.6311.7% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-034307:0
2,000 shares@ US$0.950.3% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-028784:0
3,000 shares@ US$0.920.4% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-028634:0
134,831 shares@ US$0.8917.5% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-023119:0
112,360 shares@ US$0.894.9% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-023142:0
112,360 shares@ US$0.8915.4% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-023120:0
165,841 shares@ US$1.01100.0% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-023147:0
134,831 shares@ US$0.8931.4% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-023118:0
46,296 shares@ US$1.08100.0% of flowCommon Stock, Par Value $0.001SEC:0001437749-23-023148:0
25 of 105 declarations
About Milestone Scientific INC.
Milestone Scientific Inc. is a U.S.-based medical technology company listed on NYSE American, part of the NYSE market, under the ticker MLSS. Incorporated in Delaware in August 1989, the company is headquartered in Roseland, New Jersey, United States. Its business is centered on computer-controlled injection and anesthetic delivery technologies designed to improve precision, pressure control, and patient comfort in both medical and dental procedures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm)) The company’s core platform is its proprietary Dynamic Pressure Sensing (DPS) technology. Milestone has built its product portfolio around devices that aim to deliver injectable anesthetics and other liquids more accurately than conventional manual syringes. In dentistry, its brands include The Wand®, CompuDent®, and the STA Single Tooth Anesthesia System®. In medicine, the flagship platform is CompuFlo®, including the CompuFlo Epidural Computer Controlled Anesthesia System, which the company says can provide real-time visual and audible pressure feedback to help clinicians identify the epidural space with greater objectivity. The company received FDA clearance in June 2017 to market the CompuFlo Epidural System in the United States for epidural injections. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm)) Milestone occupies a specialized niche in the broader medical devices market rather than competing as a diversified device manufacturer. Its competitive edge is built on patent protection, a differentiated clinical workflow, and claims around improved accuracy, safety, and patient experience. At the same time, the business faces a demanding regulatory environment, strong competition from larger device makers, and execution risk tied to commercialization, reimbursement, and manufacturing partnerships. The company notes that it sells dental products through a mix of exclusive and non-exclusive distributors worldwide, while medical products are sold internationally through exclusive distributors in markets such as Italy, Switzerland, Greece, Canada, and the Middle East. In the United States, medical products are marketed through a small direct sales team and a distributor partnership. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm)) Recent developments indicate a company in transition. In its March 31, 2026 business update and full-year 2025 results, management said the business had moved from restructuring toward growth, highlighting tighter spending control, a relaunch of CompuFlo commercialization efforts, and the launch of a dental ambassador program pilot. Management also signaled expectations for stronger 2026 revenue momentum and continued progress toward profitability. For equity investors, MLSS remains a micro-cap healthcare story with potentially meaningful upside if adoption improves, but it also carries elevated risk tied to product uptake, reimbursement, and capital discipline. ([nasdaq.com](https://www.nasdaq.com/press-release/milestone-scientific-reports-financial-results-fourth-quarter-and-full-year-2025-2026))
